Cyclo Therapeutics, Inc. – The New Name for CTD Holdings

Cyclo Therapeutics, Inc. (OTCQB: CTDH) has announced that it has completed its name change from CTD Holdings, Inc. following appropriate regulatory filings with the State of Florida and FINRA. 

The new name better reflects the company’s business as a biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, most notably Trappsol® Cyclo™, its proprietary hydroxypropyl beta cyclodextrin drug, for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease. The company will continue to trade on the OTCQB Exchange under the symbol CTDH. The new name was overwhelmingly approved by shareholders at their meeting on August 27th. 

“As we continue to develop our clinical programs in disease areas that can be potentially treated with Trappsol® Cyclo™, the Cyclo Therapeutics, Inc. name better reflects the Company’s main business going forward. We look forward to continued progress and higher recognition of our important biopharmaceutical products,” said Company Chairman & CEO, N. Scott Fine.

About Cyclo Therapeutics:

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is in three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (Clinical NCT02939547, NCT02912793 and NCT03893071) and in an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the company’s website:

Story Banners
Story Banners
Story Banners

Related posts